Key Takeaways:
Hansoh Pharmaceutical Group’s experimental lung cancer drug, HS-10504, received a Breakthrough Therapy designation from China's National Medical Products Administration on May 21 for patients with a specific treatment-resistant gene mutation.
The challenge of overcoming resistance to existing cancer therapies is a critical focus of oncology research. “These findings suggest BH-30643’s potential to address a significant unmet need for patients, especially those whose disease has progressed on prior EGFR TKIs,” said Xiuning Le, M.D., Ph.D., an Associate Professor at the MD Anderson Cancer Center, commenting on a similar drug.
HS-10504 is a self-developed fourth-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). The designation is for treating locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients with an EGFR C797S mutation whose disease has progressed after treatment with a prior EGFR-TKI.
The C797S mutation is a key mechanism of resistance to third-generation EGFR inhibitors like osimertinib, leaving patients with limited options and poor outcomes. The Breakthrough Therapy status is intended to fast-track the development and review of drugs for serious conditions, signaling a potential de-risking of HS-10504's path to market.
The race to treat C797S-mutant lung cancer is intensifying. US-based BlossomHill Therapeutics recently presented encouraging Phase 1 data for its own fourth-generation EGFR inhibitor, BH-30643, at the American Society of Clinical Oncology (ASCO) annual meeting. In a heavily pretreated group of patients with the C797S mutation, BH-30643 showed a 50% overall response rate in those without prior chemotherapy and 39% in those who had received chemo.
Unlike earlier generation drugs, BlossomHill's candidate is a non-covalent, macrocyclic inhibitor, representing a different chemical approach to targeting the same mutation. The development of multiple next-generation drugs highlights the significant commercial opportunity and unmet medical need in this patient population.
The regulatory acceleration for HS-10504 is a significant milestone for Hansoh Pharma, potentially solidifying its position in the competitive oncology market. Investors will now watch for the initiation of pivotal trials and subsequent data readouts to gauge the drug's efficacy and safety profile against emerging competitors.
This article is for informational purposes only and does not constitute investment advice.
